Zorbtive or serostim Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing diagnosis of growth hormone deficiency, expansion of HIV-associated wasting treatment protocols, improved recombinant hormone manufacturing processes, rising clinician awareness of anabolic therapies, availability of hospital-based hormone treatments.

The growth in the forecast period can be attributed to increasing adoption of personalized hormone therapies, rising demand for improved quality-of-life treatments, expansion of specialty pharmacy distribution, growing focus on long-acting formulations, increasing regulatory support for rare disease treatments. Major trends in the forecast period include increasing use of recombinant growth hormone therapies, rising focus on body composition improvement treatments, growing adoption of long-term hormone replacement regimens, expansion of specialized indication-based prescriptions, enhanced monitoring of therapy outcomes.

The rising number of patients with HIV is expected to drive the growth of the Zorbtive or Serostim market going forward. Human immunodeficiency virus (HIV) is a virus that weakens the immune system by targeting and destroying CD4 cells, which are crucial for fighting infections. The increasing prevalence of HIV is attributed to factors such as unprotected sexual activity, limited access to preventive healthcare, insufficient awareness and education, and barriers in testing and treatment, particularly among high-risk populations. Zorbtive or Serostim addresses HIV-associated wasting syndrome by promoting weight gain, increasing lean body mass, and improving overall physical function and quality of life for patients with compromised immune systems. For instance, in October 2024, according to the UK Health Security Agency (UKHSA), newly diagnosed HIV cases in England rose by 15%, increasing from 2,451 in 2022 to 2,810 in 2023. Therefore, the rise in HIV cases is driving growth in the Zorbtive or Serostim market.

The growth in healthcare spending and investments is expected to support the expansion of the Zorbtive or Serostim market. Healthcare spending and investment refer to the financial resources allocated by governments, private organizations, and individuals to fund healthcare services, infrastructure, research, and innovations aimed at improving public health outcomes. Rising healthcare expenditure is driven by aging populations, the increasing prevalence of chronic diseases, technological advancements, and higher demand for quality healthcare services. Increased spending facilitates access to treatments like Zorbtive or Serostim by funding research, supporting patient access programs, and ensuring insurance coverage for individuals with HIV-associated wasting syndrome. For instance, in May 2024, the Office for National Statistics, a UK-based government agency, reported that the UK’s total healthcare expenditure reached approximately $366 billion (£292 billion), reflecting a 5.6% nominal increase, with around $299 billion (£239 billion) financed by the government. Therefore, rising healthcare spending is driving the growth of the Zorbtive or Serostim market.

The increasing focus on personalized treatments is also expected to propel the growth of the Zorbtive or Serostim market. Personalized treatment tailors therapy and care to an individual’s genetic, environmental, and lifestyle factors to optimize outcomes. The demand for personalized medicine is rising due to advances in genetic research, improved diagnostic technologies, and the emphasis on more effective, targeted therapies. Zorbtive or Serostim contributes to personalized treatment by addressing HIV-associated wasting syndrome with individualized therapy that promotes weight gain, increases lean body mass, and improves physical function, catering to the unique needs of each patient and enhancing overall treatment outcomes. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six approvals in 2022. Therefore, the growing focus on personalized medicine is driving the growth of the Zorbtive or Serostim market.

Major companies operating in the zorbtive or serostim market are EMD Serono Inc.

North America was the largest region in the zorbtive or serostim market in 2025. The regions covered in the zorbtive or serostim market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the zorbtive or serostim market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the zorbtive or serostim market by increasing costs associated with imported biologic raw materials, recombinant protein processing equipment, cold-chain logistics, and specialized packaging components required for hormone therapies. Hospital pharmacies and specialty treatment centers in North America and Europe are most affected due to dependence on globally sourced biologics, while Asia-Pacific faces cost pressures in biosimilar manufacturing inputs. These tariffs are contributing to higher therapy costs and reimbursement challenges. However, they are also encouraging localized biologics manufacturing, regional supply chain investments, and long-term capacity expansion for domestic recombinant hormone production.

The zorbtive or serostim market research report is one of a series of new reports that provides zorbtive or serostim market statistics, including zorbtive or serostim industry global market size, regional shares, competitors with a zorbtive or serostim market share, detailed zorbtive or serostim market segments, market trends and opportunities, and any further data you may need to thrive in the zorbtive or serostim industry. This zorbtive or serostim market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Zorbtive and Serostim are recombinant human growth hormone therapies used to treat growth hormone deficiency, particularly in patients with conditions such as AIDS-related wasting or severe short stature. These therapies help stimulate growth, enhance protein synthesis, and improve body composition by increasing lean muscle mass and reducing fat.

The primary indications for Zorbtive and Serostim include short bowel syndrome and HIV-associated wasting. Short bowel syndrome (SBS) is a condition in which the body cannot absorb sufficient nutrients due to a reduced functional small intestine. These therapies are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used by adult and geriatric patients.

The zorbtive or serostim market consists of sales of recombinant human growth hormone products, diagnostic kits, specialty medications, and nutritional and support products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.